The Food and Drug Administration Saturday authorized administering the monoclonal antibodies casirivimab and imdevimab together to certain COVID-19 outpatients at risk for severe disease.

The Department of Health and Human Services today announced plans to allocate initial doses.

“Beginning immediately, weekly allocations to state and territorial health departments will be proportionally based on confirmed COVID-19 cases in each state and territory over the previous seven days, based on data hospitals and state health departments enter into the HHS Protect data collection platform,” the agency said.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. FDA issued the emergency use authorization to Regeneron Pharmaceuticals Inc., which makes the two investigational drugs, based on a clinical trial in 799 adults with mild-to-moderate COVID-19 symptoms.

For patients at high risk for disease progression, hospitalizations and emergency room visits occurred in 3% of patients receiving the drug combination compared to 9% in placebo-treated patients, FDA said.

Related News Articles

Headline
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday.  Pfizer said the Phase 3…
Chairperson's File
This year, I look forward to continuing AHA’s Leadership Rounds, short conversations on trending topics with health care leaders from around the country.…
Headline
The Centers for Disease Control and Prevention today reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million…
Headline
Full-dose blood thinner treatments can reduce the need for vital organ support such as ventilation in moderately ill patients hospitalized for COVID-19,…
Perspective
“We have much to do, much to repair, much to restore, much to heal, much to build … and much to gain.” President Biden focused on healing and unity in his…
Headline
The Food and Drug Administration yesterday updated its guidance and webpage on COVID-19 convalescent plasma. The updates include recommendations on when…